Gastroesophageal reflux disease pharmacotherapy is evolving beyond the proton pump inhibitor standard that has dominated management for three decades, with the Gastrointestinal Therapeutics Market reflecting the emergence of potassium-competitive acid blockers, reflux inhibitors, and bile acid binding therapy that address the limitations of PPI therapy for patients with ongoing symptoms despite...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek